SGO 2022 Conference Coverage on VuMedi
D

SGO 2022 on Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: A Cost-Effectiveness Analysis

By SGO 2022 Conference Coverage on VuMedi FEATURING David Barrington
By SGO 2022 Conference Coverage on VuMedi FEATURING David Barrington
232 views
April 7, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Cleveland Clinic Respiratory Institute

Advanced Diagnostic Bronchoscopy Workshop

Fri, Jun 14, 2024
Fox Chase Cancer Center

2024 Atlantic Regional Hematopathology Meeting

Sat, May 11, 2024
Penn Medicine Abramson Cancer Center

Updates in Oncology 2024 Philadelphia: with Proceedings from Interna…

Wed, Jun 12, 2024
UChicago Medicine

27th University of Chicago Comprehensive Cancer Center Developmental…

Fri, May 10, 2024
Vanderbilt University Medical Center (VUMC)

Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium

Sat, May 11, 2024
Yale Cancer Center

Gastrointestinal Cancer CME Series: Gastroesophogeal Cancer

Thu, May 23, 2024
See 1 other
COR2ED The Heart of Medical Education

Precision Oncology in Practice - The Journey from Testing to Treatme…

Tue, Apr 30, 2024
See 1 other
European Research Initiative on CLL - ERIC

ERIC International Meeting 2024 - New Frontiers in CLL Research

Thu, Sep 26, 2024
i3 Health

Live Webinar: Hitting the Target in HER2-Positive Metastatic Colorec…

Mon, Apr 29, 2024
See 2 others
MI&T Congressi

3rd International Summit on Lung Cancer

Sun, May 5, 2024
SOHO Brazil

SOHO Brazil 2024

Thu, May 16, 2024
Total Health

MDONS Metro Denver Chapter Conference

Fri, May 17, 2024
06:07
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
04:02
Total Health

2024 Updates in Cervical Cancer

Feat. T. Tillmanns
44:59
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Updates on Cervical and Endometrial Cancers

Feat. K. Pennington
12:45
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The GCIG INTERLACE Randomised Phase 3 Tria…

Feat. M. McCormack
13:41
UCLA Health

2024 Updates in Locally Advanced Cervical Cancer

Feat. D. Chase
04:58
Oncology Data Advisor

Tisotumab Vedotin for Metastatic Cervical Cancer: Updates From ESMO …

Feat. B. Slomovitz
11:37
UCLA Health

Recurrent Cervical Cancer Updates

Feat. R. Salani
11:10
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "KEYNOTE-A18 Study - Pembro + CRT for High-…

Feat. D. Lorusso
23:38
Insights from 2023 IGCS Annual Meeting

IGCS 2023 Insights: "Is Immunotherapy Beating Stage 4B, Persist…

Feat. N. Colombo
28:26
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

The Role of Immunotherapy and Targeted Therapy in GYN Cancers

Feat. S. Gaillard
10:14
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Integrating Immunotherapy Into the Treatment of Cervical Cancer

Feat. A. Wright
25:03
Total Health

Hungry for Data: The Connection Between Diet and Cancer and Selected…

Feat. T. Berman
18:55
Nebraska Oncology Society

Updates in Cervical Cancer: SHAPE Trial, KEYNOTE-826 & innovaTV …

Feat. M. Clark
14:18
ImmunoTherapy Bridge 2023

How Immunotherapy Changed the Treatment Story for Endometrial and Ce…

Feat. M. Bartoletti
02:38
ecancer

ESMO 2023 Insights: "Pembro + CRT For High-Risk Locally Advance…

Feat. D. Lorusso
01:59
ecancer

ESMO 2023 Insights: "Phase 3 GCIG INTERLACE Trial - Induction C…

Feat. M. McCormack
12:48
ASCO GU 2023 Conference Coverage

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A …

Feat. M. Kohli
15:09
ImmunoTherapy Bridge 2023

Best of SITC 2023 for Clinical Development and IO Trials

Feat. P. A. Ascierto
10:48
Integrity Continuing Education

Cervical Chronicles: Navigating the Evolving Landscape of Treatment

Feat. M. Murphy